26 February 2025
ONDINE BIOMEDICAL
INC.
("Ondine
Biomedical", "Ondine", or the "Company")
Ondine Biomedical Strengthens Leadership Team with the
Appointment of Michael Behlke as non-Board CFO &
COO
Ondine Biomedical Inc. (LON: OBI), a
global leader in light-activated antimicrobial treatments, is
pleased to announce the appointment of Michael S. Behlke as Chief Financial Officer (CFO) and Chief Operating Officer
(COO), effective immediately. Recognized in the US
MedTech community for his career achievements, Mr. Behlke brings
over 30 years of financial and operational leadership experience,
positioning Ondine for accelerated growth and commercialization
success.
Mr. Behlke's distinguished career
includes securing over $250 million in funding, supporting
acquisitions exceeding $700 million, and driving commercialization
strategies for emerging and mid-stage medical companies. Prior to
joining Ondine, he served as CFO and Acting COO at Ventec Life
Systems with full P&L responsibility, where he played a
critical role in scaling the company's revenue from $13 million to
$500 million annually and in its landmark partnership with General
Motors to rapidly scale up and manufacture ventilators for the US
Strategic National Stockpile during the COVID-19
pandemic.
Carolyn Cross, Ondine's
Chief Executive Officer:
"We are thrilled to welcome Michael to our leadership team.
Ondine is at a critical inflection point as we expand our
hospital-based infection prevention solutions. Michael's extensive
MedTech industry experience, operational leadership, and business
transformation successes will be key to accelerating our worldwide
commercialization efforts, initially within Canada and the UK/EU,
and then rapidly expanding into the U.S. post-FDA
approval."
In his new role, Mr. Behlke will
oversee Ondine's capital markets strategies, operational
efficiency, and international expansion, ensuring the company's is
well-positioned for sustained growth and market leadership. His
deep expertise in P&L management, business transformation, and
supply chain execution will be key to advancing Ondine's mission of
revolutionizing infection prevention through its
photodisinfection-based platform technology.
Michael Behlke, CFO &
COO of Ondine Biomedical:
"I
am honored to join Ondine at this pivotal moment. The company's
groundbreaking photodisinfection technology represents a paradigm
shift in infection control. I look forward to working with this
talented team to drive operational excellence, financial growth,
and global adoption of this life-saving
technology."
This appointment strengthens
Ondine's leadership team and underscores the Company's commitment
to expanding its footprint in key global markets and addressing the
urgent need for innovative antimicrobial solutions in healthcare
settings.
Enquiries:
|
Ondine Biomedical
Inc.
|
www.ondinebio.com
|
|
Carolyn Cross, CEO
|
Via Vane Percy &
Roberts
|
|
Strand Hanson Limited (Nominated & Financial
Adviser)
|
|
|
James Harris, Richard
Johnson
|
+44 (0)20 7409 3494
|
|
|
|
|
RBC
Capital Markets (Broker)
|
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20 7653 4000
|
|
|
|
|
Vane Percy & Roberts (Media Contact)
|
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77 1000 5910
|
About Ondine Biomedical
Inc.
Ondine Biomedical Inc. is a Canadian
life sciences company and leader in light-activated antimicrobial
therapies (also known as 'photodisinfection') to prevent and treat
infections, including those caused by antibiotic-resistant
bacteria. Ondine's patented light-activated antimicrobial
technology offers a safe, rapid, and effective alternative to
traditional antibiotics, tackling some of the most pressing
healthcare challenges today.
